Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2022-09-07 00:00:00 ET · period of report 2022-09-02 · accession 0001209191-22-049015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-09-07 | 2022-09-02 | XENE | AULIN SHERRY | CFO | M - OptEx | $6.97 | +18.6K | 9,032 | New | +$130.1K |
| D | 2022-09-07 | 2022-09-02 | XENE | AULIN SHERRY | CFO | F - Tax | $39.53 | -3,293 | 15.4K | -18% | -$130.2K |
| D | 2022-09-07 | 2022-09-02 | XENE | AULIN SHERRY | CFO | S - Sale+OE | $39.57 | -15.4K | 0 | -100% | -$607.6K |
| DM | 2022-09-07 | 2022-09-02 | XENE | AULIN SHERRY | CFO | M - OptEx | $0.00 | -18.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-09-02 | M | A | 2,292 | $3.10 | 12,137 | D | — | — | |
| 2 | Common | Common Shares | 2022-09-02 | M | A | 6,511 | $4.75 | 18,648 | D | — | — | |
| 3 | Common | Common Shares | 2022-09-02 | F | D | 3,293 | $39.53 | 15,355 | D | — | — | (F1) Represents the closing price of the Company's common shares on September 1, 2022 for purposes of net settlement calculations. |
| 4 | Common | Common Shares | 2022-09-02 | M | A | 813 | $8.40 | 9,845 | D | — | — | |
| 5 | Common | Common Shares | 2022-09-02 | S | D | 15,355 | $39.57 | 0 | D | — | — | (F2) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 6 | Common | Common Shares | 2022-09-02 | M | A | 9,000 | $9.44 | 9,000 | D | — | — | |
| 7 | Common | Common Shares | 2022-09-02 | M | A | 32 | $7.49 | 9,032 | D | — | — | |
| 8 | Derivative | Stock Option (Right to Buy) | 2022-09-02 | M | D | 6,511 | $0.00 | 0 | D | $4.75 · — to 2028-03-11 | 6,511 Common Shares | (F3) The shares subject to the option are fully vested and exercisable. |
| 9 | Derivative | Stock Option (Right to Buy) | 2022-09-02 | M | D | 2,292 | $0.00 | 0 | D | $3.10 · — to 2027-10-22 | 2,292 Common Shares | (F3) The shares subject to the option are fully vested and exercisable. |
| 10 | Derivative | Stock Option (Right to Buy) | 2022-09-02 | M | D | 9,000 | $0.00 | 0 | D | $9.44 · — to 2029-09-15 | 9,000 Common Shares | (F3) The shares subject to the option are fully vested and exercisable. |
| 11 | Derivative | Stock Option (Right to Buy) | 2022-09-02 | M | D | 32 | $0.00 | 0 | D | $7.49 · — to 2026-03-10 | 32 Common Shares | (F3) The shares subject to the option are fully vested and exercisable. |
| 12 | Derivative | Stock Option (Right to Buy) | 2022-09-02 | M | D | 813 | $0.00 | 0 | D | $8.40 · — to 2027-03-12 | 813 Common Shares | (F3) The shares subject to the option are fully vested and exercisable. |